Logo image of INNV

INNOVAGE HOLDING CORP (INNV) Stock Fundamental Analysis

NASDAQ:INNV - Nasdaq - US45784A1043 - Common Stock - Currency: USD

2.75  -0.09 (-3.17%)

After market: 2.75 0 (0%)

Fundamental Rating

2

Taking everything into account, INNV scores 2 out of 10 in our fundamental rating. INNV was compared to 106 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of INNV have multiple concerns. INNV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year INNV has reported negative net income.
INNV had a positive operating cash flow in the past year.
In the past 5 years INNV reported 4 times negative net income.
In multiple years INNV reported negative operating cash flow during the last 5 years.
INNV Yearly Net Income VS EBIT VS OCF VS FCFINNV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

INNV has a Return On Assets of -4.90%. This is in the lower half of the industry: INNV underperforms 66.98% of its industry peers.
Looking at the Return On Equity, with a value of -10.36%, INNV is in line with its industry, outperforming 41.51% of the companies in the same industry.
Industry RankSector Rank
ROA -4.9%
ROE -10.36%
ROIC N/A
ROA(3y)-4.08%
ROA(5y)-2.82%
ROE(3y)-7.87%
ROE(5y)-2.14%
ROIC(3y)N/A
ROIC(5y)N/A
INNV Yearly ROA, ROE, ROICINNV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

With a Gross Margin value of 17.63%, INNV is not doing good in the industry: 65.09% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of INNV has declined.
INNV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.12%
GM growth 5Y-6.16%
INNV Yearly Profit, Operating, Gross MarginsINNV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

3

2. Health

2.1 Basic Checks

INNV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INNV has been increased compared to 1 year ago.
Compared to 5 years ago, INNV has more shares outstanding
Compared to 1 year ago, INNV has an improved debt to assets ratio.
INNV Yearly Shares OutstandingINNV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
INNV Yearly Total Debt VS Total AssetsINNV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

INNV has an Altman-Z score of 2.04. This is not the best score and indicates that INNV is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.04, INNV is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Debt/Equity ratio of 0.28 indicates that INNV is not too dependend on debt financing.
INNV has a better Debt to Equity ratio (0.28) than 66.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z 2.04
ROIC/WACCN/A
WACC8.06%
INNV Yearly LT Debt VS Equity VS FCFINNV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

INNV has a Current Ratio of 1.16. This is a normal value and indicates that INNV is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.16, INNV is not doing good in the industry: 66.04% of the companies in the same industry are doing better.
INNV has a Quick Ratio of 1.16. This is a normal value and indicates that INNV is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.16, INNV perfoms like the industry average, outperforming 40.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
INNV Yearly Current Assets VS Current LiabilitesINNV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.83% over the past year.
Looking at the last year, INNV shows a quite strong growth in Revenue. The Revenue has grown by 11.91% in the last year.
The Revenue has been growing by 10.41% on average over the past years. This is quite good.
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)11.91%
Revenue growth 3Y6.2%
Revenue growth 5Y10.41%
Sales Q2Q%10.64%

3.2 Future

INNV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.21% yearly.
INNV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.60% yearly.
EPS Next Y10.15%
EPS Next 2Y57.28%
EPS Next 3Y51.21%
EPS Next 5YN/A
Revenue Next Year12.13%
Revenue Next 2Y11.21%
Revenue Next 3Y11.6%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
INNV Yearly Revenue VS EstimatesINNV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
INNV Yearly EPS VS EstimatesINNV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INNV. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 41.48, which means the current valuation is very expensive for INNV.
The rest of the industry has a similar Price/Forward Earnings ratio as INNV.
INNV's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.08.
Industry RankSector Rank
PE N/A
Fwd PE 41.48
INNV Price Earnings VS Forward Price EarningsINNV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INNV indicates a slightly more expensive valuation: INNV is more expensive than 63.21% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 216.45
INNV Per share dataINNV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
INNV's earnings are expected to grow with 51.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.28%
EPS Next 3Y51.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INNV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNOVAGE HOLDING CORP

NASDAQ:INNV (4/17/2025, 4:30:02 PM)

After market: 2.75 0 (0%)

2.75

-0.09 (-3.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-04 2025-02-04/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners11.86%
Inst Owner Change0%
Ins Owners1.54%
Ins Owner Change0%
Market Cap371.91M
Analysts48
Price Target5.95 (116.36%)
Short Float %1.83%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-148.37%
Min EPS beat(2)-292.16%
Max EPS beat(2)-4.58%
EPS beat(4)1
Avg EPS beat(4)-62.12%
Min EPS beat(4)-292.16%
Max EPS beat(4)62.77%
EPS beat(8)2
Avg EPS beat(8)-55.48%
EPS beat(12)3
Avg EPS beat(12)-88.49%
EPS beat(16)4
Avg EPS beat(16)-71.82%
Revenue beat(2)0
Avg Revenue beat(2)-1.84%
Min Revenue beat(2)-2.58%
Max Revenue beat(2)-1.09%
Revenue beat(4)2
Avg Revenue beat(4)-0.26%
Min Revenue beat(4)-2.58%
Max Revenue beat(4)2.09%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)5
Avg Revenue beat(12)-0.81%
Revenue beat(16)6
Avg Revenue beat(16)-0.6%
PT rev (1m)0%
PT rev (3m)6.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.04%
EPS NY rev (1m)-23.33%
EPS NY rev (3m)-82.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 41.48
P/S 0.46
P/FCF N/A
P/OCF 80.53
P/B 1.5
P/tB 3.57
EV/EBITDA 216.45
EPS(TTM)-0.12
EYN/A
EPS(NY)0.07
Fwd EY2.41%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.03
OCFY1.24%
SpS5.96
BVpS1.84
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.9%
ROE -10.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.63%
FCFM N/A
ROA(3y)-4.08%
ROA(5y)-2.82%
ROE(3y)-7.87%
ROE(5y)-2.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.12%
GM growth 5Y-6.16%
F-Score6
Asset Turnover1.54
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 46.21
Cap/Depr 34.56%
Cap/Sales 0.91%
Interest Coverage N/A
Cash Conversion 310.35%
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z 2.04
F-Score6
WACC8.06%
ROIC/WACCN/A
Cap/Depr(3y)155.97%
Cap/Depr(5y)146.35%
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y10.15%
EPS Next 2Y57.28%
EPS Next 3Y51.21%
EPS Next 5YN/A
Revenue 1Y (TTM)11.91%
Revenue growth 3Y6.2%
Revenue growth 5Y10.41%
Sales Q2Q%10.64%
Revenue Next Year12.13%
Revenue Next 2Y11.21%
Revenue Next 3Y11.6%
Revenue Next 5YN/A
EBIT growth 1Y37.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year219.92%
EBIT Next 3Y73.37%
EBIT Next 5YN/A
FCF growth 1Y96.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y117.58%
OCF growth 3YN/A
OCF growth 5YN/A